Platelet Biology in Focus – Current Opinion in Hematology 2026
Dianne E. van der Wal, Researcher at ANZAC Research Institute (Sydney Local Health District), shared a post by Current Opinion in Hematology on LinkedIn:
”Another great selection of platelet papers.”
Quoting Current Opinion in Hematology’s post:
”As we come to the end of 2025 and look forward to seeing in the New Year, fancy an early look to 2026. Our January 2026 issue of Current Opinion in Hematology is here, with a focus on Platelet Biology.
Joseph Aslan from Oregon Health & Science University highlights recent studies of platelet proteomes and platelet function in development, aging, and disease. Insights emphasize that the platelet proteome encodes both physiologic adaptability and maladaptive responses in pathology.
Next, we have a review on cellular contributions to the pathogenesis of anti-platelet factor 4 disorders, by Jared Treverton, Mark Lychacz, Donald Arnold, and Ishac Nazy, McMaster University
Mariia (Masha) Naumenko et al. analyze established platelet isolation protocols, clarifying their rationale and key overlooked factors. Their review explores the potential of modern strategies and emerging technologies, particularly artificial intelligence, to transform platelet research.
And in the review ‘Platelet concentrates in periodontics: a journey through platelet-rich plasma, platelet-rich fibrin and their therapeutic uses: a literature update’, Supreet Kaur et al. emphasize the pivotal function of platelet concentrates in advancing regenerative periodontal therapy. The authors conclude that concentrates offer a transformative advancement in periodontal therapy, leveraging the body’s natural healing processes to achieve superior clinical outcomes.
Full TOC here.
Thank you to our authors for their contributions, and to our Section Editors Joshua Mui and Colin Kretz for their hard work on bringing together this great section.
Wishing you all a wonderful festive season, and thank you for your support for the journal. Looking forward to sharing more important and insightful content with you next year.”

Keep up with Hemostasis Today.
-
Feb 23, 2026, 14:45Stacey McGeown: Rare Disease Awareness Day at QUB Marks the Start of Rare Disease Month
-
Feb 23, 2026, 13:53Rare Diseases, Plasma-Derived Medicines and the Elephant in the Room – Part 1
-
Feb 23, 2026, 13:02Deepak Yadav: What 2025 Evidence Tells Us About Stroke Care
-
Feb 23, 2026, 12:55Radoslaw Kaczmarek: Will AAV Gene Therapy for Hemophilia Trigger Tumorigenesis?
-
Feb 23, 2026, 12:46Heghine Khachatryan: More Granular Risk Stratification Framework for PE from The New 2026 AHA/ACC Guideline
-
Feb 23, 2026, 12:37Reza Shojaei: EU’s Critical Medicines Act and Plasma Resilience
-
Feb 23, 2026, 12:32Anirban Sen Gupta: Emily Mihalko Highlights PlateChek at MTEC
-
Feb 23, 2026, 12:25Ryan Williams: Excellent Highlights on The Heterogeneity of PRP Preparation
-
Feb 23, 2026, 12:10Peter Libby: hsCRP May Select Patients Who Can Benefit From Statins or Anti-inflammatory Therapy